Dr. Paul Sax follows up his post about whether or not an HIV patient's treatment regimen could be simplified, in
HIV and ID Observations.
In the latest HIV and ID Observations, Dr. Paul Sax reviews results from last week's poll and highlights studies that show that ongoing nucleoside reversetranscriptase inhibitor (NRTI) activity in the setting of genotypic resistance is “the real deal.”
Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Subscribe box.
Want to see more from NEJM Journal Watch? Register here.